How High Will Roku Stock Go?
Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…
Sell
46
PCVX Quote, Financials, Valuation and Earnings
Last price:
$34.56
Seasonality move
:
32.4%
Day range:
$33.55 - $34.70
52-week range:
$27.66 - $121.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.39x
Volume:
1.2M
Avg. volume:
2.1M
1-year change:
-53.3%
Market cap:
$4.5B
Revenue:
--
EPS (TTM):
-$3.99
Analysts' Opinion
-
Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $125.75, Vaxcyte has an estimated upside of 263.86% from its current price of $34.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $65.00 representing 100% downside risk from its current price of $34.56.
Fair Value
-
According to the consensus of 9 analysts, Vaxcyte has 263.86% upside to fair value with a price target of $125.75 per share.
PCVX vs. S&P 500
-
Over the past 5 trading days, Vaxcyte has underperformed the S&P 500 by -6.2% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Vaxcyte does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vaxcyte has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vaxcyte reported revenues of --.
Earnings Growth
-
Vaxcyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Vaxcyte reported earnings per share of -$1.04.
Enterprise value:
2.8B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.69x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$240.7M | -$437M | -$636M | -$114.5M | -$180.8M | |
| EBITDA | -$245.6M | -$435.3M | -$512.7M | -$111.4M | -$175.9M | |
| Diluted EPS | -$3.45 | -$4.28 | -$3.99 | -$0.85 | -$1.04 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $324.7M | $342.2M | $840.7M | $1.5B | $1.7B | |
| Total Assets | $382.4M | $402.7M | $1B | $2.1B | $3.4B | |
| Current Liabilities | $55M | $27.2M | $52.7M | $87.1M | $97M | |
| Total Liabilities | $55.4M | $43.2M | $63.4M | $107.3M | $178.1M | |
| Total Equity | $326.9M | $359.5M | $944.8M | $2B | $3.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$190.6M | -$408.2M | -$459.8M | -$159.1M | -$166.3M | |
| Cash From Investing | -$423.2M | -$776.3M | -$1.4B | -$451.1M | $123.3M | |
| Cash From Financing | $792.1M | $1.4B | $1.6B | $818.2M | $759K | |
| Free Cash Flow | -$199.1M | -$482.6M | -$593.6M | -$171.2M | -$193M | |
PCVX
Sector
Market Cap
$4.5B
$33.4M
Price % of 52-Week High
28.55%
46.84%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-53.3%
-37.4%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$35.56
200-day SMA
Sell
Level
$77.09
Bollinger Bands (100)
Sell
Level
30.83 - 79.31
Chaikin Money Flow
Sell
Level
-2.6M
20-day SMA
Buy
Level
$34.17
Relative Strength Index (RSI14)
Sell
Level
49.20
ADX Line
Sell
Level
16.46
Williams %R
Neutral
Level
-52.31
50-day SMA
Buy
Level
$32.68
MACD (12, 26)
Buy
Level
0.14
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
42.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Stock Forecast FAQ
In the current month, PCVX has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PCVX average analyst price target in the past 3 months is $125.75.
-
Where Will Vaxcyte Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vaxcyte share price will rise to $125.75 per share over the next 12 months.
-
What Do Analysts Say About Vaxcyte?
Analysts are divided on their view about Vaxcyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vaxcyte is a Sell and believe this share price will drop from its current level to $65.00.
-
What Is Vaxcyte's Price Target?
The price target for Vaxcyte over the next 1-year time period is forecast to be $125.75 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PCVX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vaxcyte is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PCVX?
You can purchase shares of Vaxcyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vaxcyte shares.
-
What Is The Vaxcyte Share Price Today?
Vaxcyte was last trading at $34.56 per share. This represents the most recent stock quote for Vaxcyte. Yesterday, Vaxcyte closed at $34.56 per share.
-
How To Buy Vaxcyte Stock Online?
In order to purchase Vaxcyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will The Trade Desk’s Stock Be in 5 Years?
If you stitched together every advertisement The Trade Desk (NASDAQ:…
Is MSTR Stock Fundamentally Misunderstood?
Software firm turned Bitcoin treasury Strategy (NASDAQ:MSTR) has made waves…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 48x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Buy
74
DAVE alert for Jun 14
Dave [DAVE] is down 12.68% over the past day.
Buy
54
DAR alert for Jun 14
Darling Ingredients [DAR] is up 9.12% over the past day.
Sell
9
NAIL alert for Jun 14
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is down 8.8% over the past day.
